Liikmemaksu info: 
Seltsi liikmemaksu 6,5 EUR palume kanda 1. maiks
ELHS arvelduskontole EE901700017001881224 Luminor pangas
Parkinsoni tõve ravijuhend
Ravijuhendid

Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E., Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõve Eesti ravijuhend Parkinsoni tõve Eesti ravijuhend: 102, 2008

Linnamägi Ü., Vahter L., Jaanson K., Tomberg T., Lüüs SM., Gross-Paju K., Kreis A., Toomsoo T. Dementsuse Eesti ravi-, tegevus- ja diagnostikajuhend Dementsuse Eesti ravi-, tegevus- ja diagnostikajuhend: 43, 2007

Patsiendijuhend:

Parkinsoni tõbi

 

Rahvusvahelised publikatsioonid:

Liu G, Ni C, Zhan J, Li W, …Taba P, et al. Mitochondrial haplogroups and cognitive progression in Parkinson's disease. Brain. 2023;146(1):42-9.

Sugier PE, Lucotte EA, Domenighetti C, …Taba P, et al. Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers. Mov Disord. 2023;38(4):604-15.

Boutet A, Loh A, Germann J, Machnowska M, Scantlebury N, Vetkas A, et al. A Cautionary Tale of Magnetic Resonance-Guided Focused Ultrasound Thalamotomy-Induced White Matter Lesions. Mov Disord. 2022;37(9):1953-5.

Brunklaus A, Brünger T, Feng T, ..Vaher U, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022;145(11):3816-31.

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, et al. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Eur J Neurol. 2022;29(9):2580-95.

Deuschl G, Antonini A, Costa J, …Taba P, et al. European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. Mov Disord. 2022;37(7):1360-74.

Domenighetti C, Douillard V, …Taba P, et al. The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited. Mov Disord. 2022;37(9):1929-37.

Domenighetti C, Sugier PE, ..Taba P, et al. Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Mov Disord. 2022;37(4):857-64.

Domenighetti C, Sugier PE, Sreelatha AAK, …Taba P, et al. Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. J Parkinsons Dis. 2022;12(1):267-82.

Grover S, Kumar Sreelatha AA, Pihlstrom L, …Taba P, et al. Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium. Neurology. 2022;99(7):e698-e710.

Loh A, Gwun D, Chow CT, Boutet A, Tasserie J, Germann J, et al. Probing responses to deep brain stimulation with functional magnetic resonance imaging. Brain Stimul. 2022;15(3):683-94.

Medijainen K, Pääsuke M, Lukmann A, Taba P. Structured guideline-based physiotherapy reduces difficulties in activities of daily living in Parkinson's disease. NeuroRehabilitation. 2022;50(1):47-56.

Branovets J, Karro N, Barsunova K, Laasmaa M, Lygate CA, Vendelin M, et al. Cardiac expression and location of hexokinase changes in a mouse model of pure creatine deficiency. Am J Physiol Heart Circ Physiol. 2021;320(2):H613-h29.

Gatsios D, Antonini A, Gentile G, …Taba P, et al. Education on palliative care for Parkinson patients: development of the "Best care for people with late-stage Parkinson's disease" curriculum toolkit. BMC Med Educ. 2021;21(1):538.

Innos J, Hickey MA. Using Rotenone to Model Parkinson's Disease in Mice: A Review of the Role of Pharmacokinetics. Chem Res Toxicol. 2021;34(5):1223-39.

Kurvits L, Lättekivi F, Reimann E, Kadastik-Eerme L, Kasterpalu KM, Kõks S, et al. Transcriptomic profiles in Parkinson's disease. Exp Biol Med (Maywood). 2021;246(5):584-95.

Kwong AK, Tsang MH, Fung JL, Mak CC, Chan KL, Rodenburg RJT, et al. Exome sequencing in paediatric patients with movement disorders. Orphanet J Rare Dis. 2021;16(1):32.

Liu G, Peng J, Liao Z, Locascio JJ, …Taba P, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet. 2021;53(6):787-93.

Mencacci NE, Brockmann MM, Dai J, Pajusalu S, Atasu B, Campos J, et al. Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. J Clin Invest. 2021;131(7).

Muldmaa M, Mencacci NE, Pittman A, Kadastik-Eerme L, Sikk K, Taba P, et al. Community-based genetic study of Parkinson's disease in Estonia. Acta Neurol Scand. 2021;143(1):89-95.

Nurm K, Sepp M, Castany-Pladevall C, Creus-Muncunill J, Tuvikene J, Sirp A, et al. Isoform-Specific Reduction of the Basic Helix-Loop-Helix Transcription Factor TCF4 Levels in Huntington's Disease. eNeuro. 2021;8(5).

Renko JM, Mahato AK, Visnapuu T, Valkonen K, Karelson M, Voutilainen MH, et al. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. J Parkinsons Dis. 2021;11(3):1023-46.

Sarica C, Fomenko A, Iorio-Morin C, Zemmar A, Yamamoto K, Vetkas A, et al. Letter to the Editor. Clinical Rating Scale for Tremor: a needed clarification. J Neurosurg. 2021;136(3):932-3.

Beck DB, Petracovici A, He C, Moore HW, Louie RJ, Ansar M, et al. Delineation of a Human Mendelian Disorder of the DNA Demethylation Machinery: TET3 Deficiency. Am J Hum Genet. 2020;106(2):234-45.

Ennok M, Sikk K, Haldre S, Taba P. Cognitive profile of patients with manganese-methcathinone encephalopathy. Neurotoxicology. 2020;76:138-43.

Mahato AK, Kopra J, Renko JM, Visnapuu T, Korhonen I, Pulkkinen N, et al. Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo. Mov Disord. 2020;35(2):245-55.

Tamás G, Fabbri M, Falup-Pecurariu C, Teodoro T, … Kadastik-Eerme L, et al. Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. J Parkinsons Dis. 2020;10(4):1833-43.

Whiffin N, Armean IM, Kleinman A, …Esko T, et al. The effect of LRRK2 loss-of-function variants in humans. Nat Med. 2020;26(6):869-77.

Billingsley KJ, Lättekivi F, Planken A, Reimann E, Kurvits L, Kadastik-Eerme L, et al. Analysis of repetitive element expression in the blood and skin of patients with Parkinson's disease identifies differential expression of satellite elements. Sci Rep. 2019;9(1):4369.

Kadastik-Eerme L, Taba N, Asser T, Taba P. Incidence and Mortality of Parkinson's Disease in Estonia. Neuroepidemiology. 2019;53(1-2):63-72.

Kolk A, Saard M, Pertens L, Kallakas T, Sepp K, Kornet K. Structured Model of Neurorehab: A Pilot Study of Modern Multitouch Technology and Virtual Reality Platforms for Training Sociocognitive Deficit in Children with Acquired Brain Injury. Appl Neuropsychol Child. 2019;8(4):326-32.

Lubi K. The adaptation of everyday practices in the adoption of chronic illness. Health (London). 2019;23(3):325-43.

Medijainen K, Pääsuke M, Lukmann A, Taba P. Versatile guideline-based physiotherapy intervention in groups to improve gait speed in Parkinson's disease patients. NeuroRehabilitation. 2019;44(4):579-86.

Randver R, Davel K, Toomsoo T. High-frequency repetitive transcranial magnetic stimulation to the left dorsolateral prefrontal cortex of patients with Parkinson's disease and treatment-resistant depression: a pilot study. Neurocase. 2019;25(3-4):80-90.

Rätsep T, Asser T. Influence of alarming auditory cues on viscoelastic stiffness of skeletal muscles in patients with Parkinson's disease. Clin Biomech (Bristol, Avon). 2019;62:93-5.

Toomsoo T, Liepelt-Scarfone I, Berg D, Kerner R, Pool AH, Kadastik-Eerme L, et al. Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls. Ultrasound Med Biol. 2019;45(1):122-8.

Yakoreva M, Kahre T, Žordania R, Reinson K, Teek R, Tillmann V, et al. A retrospective analysis of the prevalence of imprinting disorders in Estonia from 1998 to 2016. Eur J Hum Genet. 2019;27(11):1649-58.

Randver R. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson's disease: A review and clinical implications. J Neurol Sci. 2018;393:88-99.

Altpere A, Raud S, Sütt S, Reimets R, Visnapuu T, Toots M, Vasar E. Mild stress induces brain region-specific alterations of selective ER stress markers' mRNA expression in Wfs1-deficient mice. Behav Brain Res. 2018 Oct 15;352:94-98

Kadastik-Eerme L, Taba N, Asser T, Taba P. The increasing prevalence of Parkinson's disease in Estonia. Acta Neurol Scand. 2018 Sep;138(3):251-258

Römhild J, Fleischer S, Meyer G, Stephan A, Zwakhalen S, Leino-Kilpi H, Zabalegui A, Saks K, Soto-Martin M, Sutcliffe C, Rahm Hallberg I, Berg A; RightTimePlaceCare Consortium.. Inter-rater agreement of the Quality of Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: secondary analysis of RightTimePlaceCare data. Health Qual Life Outcomes. 2018 Jun 28;16(1):131

Tiigimäe-Saar J, Tamme T, Rosenthal M, Kadastik-Eerme L, Taba P. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A. Neurol Sci. 2018 May;39(5):871-877

Ivask M, Pajusalu S, Reimann E, Kõks S. Hippocampus and Hypothalamus RNA-sequencing of WFS1-deficient Mice. Neuroscience. 2018 Mar 15;374:91-103.

Bradburn S, McPhee J, Bagley L, Carroll M, Slevin M, Al-Shanti N, Barnouin Y, Hogrel JY, Pääsuke M, Gapeyeva H, Maier A, Sipilä S, Narici M, Robinson A, Mann D, Payton A, Pendleton N, Butler-Browne G, Murgatroyd C. Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance. Neurobiol Aging. 2018 Mar;63:54-64

Smirnova J, Kabin E, Järving I, Bragina O, Tõugu V, Plitz T, Palumaa P. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. a-Lipoic acid as a potential anti-copper agent. Sci Rep. 2018 Jan 23;8(1):1463

Yau Y, Zeighami Y, Baker TE, Larcher K, Vainik U, Dadar M, Fonov VS, Hagmann P, Griffa A, Mišic B, Collins DL, Dagher A. Network connectivity determines cortical thinning in early Parkinson's disease progression. Nat Commun. 2018 Jan 2;9(1):12

Porosk R, Terasmaa A, Mahlapuu R, Soomets U, Kilk K. Metabolomics of the Wolfram Syndrome 1 Gene (Wfs1) Deficient Mice. OMICS. 2017 Dec;21(12):721-732

Mann AP, Scodeller P, Hussain S, Braun GB, Mölder T, Toome K, Ambasudhan R, Teesalu T, Lipton SA, Ruoslahti E. Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun. 2017 Nov 10;8(1):1403. doi: 10.1038/s41467-017-01096-0. Erratum in: Nat Commun. 2018 Mar 9;9(1):10705.

Porosk R, Kilk K, Mahlapuu R, Terasmaa A, Soomets U. Glutathione system in Wolfram syndrome 1-deficient mice. Mol Med Rep. 2017 Nov;16(5):7092-7097

Toomsoo T, Randver R, Liepelt-Scarfone I, Kadastik-Eerme L, Asser T, Rubanovits I, Berg D, Taba P. Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson's disease and non-PD controls. Psychiatry Res Neuroimaging. 2017 Oct 30;268:45-49

Kadastik-Eerme L, Taba N, Asser T, Taba P. Factors associated with motor complications in Parkinson's disease. Brain Behav. 2017 Sep 25;7(10):e00837

Georgiopoulos G, Chrysohoou C, Errigo A, Pes G, Metaxa V, Zaromytidou M, Skoumas J, Kariori M, Lazaros G, Vogiatzi G, Poulain M, Tousoulis D, Pitsavos C, Stefanadis C. Arterial aging mediates the effect of TNF-a and ACE polymorphisms on mental health in elderly individuals: insights from IKARIA study. QJM. 2017 Sep 1;110(9):551-557

Astuti D, Sabir A, Fulton P, Zatyka M, Williams D, Hardy C, Milan G, Favaretto F, Yu-Wai-Man P, Rohayem J, López de Heredia M, Hershey T, Tranebjaerg L, Chen JH, Chaussenot A, Nunes V, Marshall B, McAfferty S, Tillmann V, Maffei P, Paquis-Flucklinger V, Geberhiwot T, Mlynarski W, Parkinson K, Picard V, Bueno GE, Dias R, Arnold A, Richens C, Paisey R, Urano F, Semple R, Sinnott R, Barrett TG. Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram, and Thiamine-responsive megaloblastic anemia. Hum Mutat. 2017 Jul;38(7):764-777

Rätsep T, Asser T. The effect of subthalamic stimulation on viscoelastic stiffness of skeletal muscles in patients with Parkinson's disease. Clin Biomech (Bristol, Avon). 2017 May;44:94-98

Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P, Wüllner U. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. Genome Med. 2017 Apr 28;9(1):39. doi: 10.1186/s13073-017-0428-y. Erratum in: Genome Med. 2017 Jun 29;9(1):61

Planken A, Kurvits L, Reimann E, Kadastik-Eerme L, Kingo K, Kõks S, Taba P. Looking beyond the brain to improve the pathogenic understanding of Parkinson's disease: implications of whole transcriptome profiling of Patients' skin. BMC Neurol. 2017 Jan 10;17(1):6

Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA consortium and TOSCA investigators.. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017 Jan 5;12(1):2

Beheshti I, Maikusa N, Matsuda H, Demirel H, Anbarjafari G; Japanese-Alzheimer’s Disease Neuroimaging Initiative.. Histogram-Based Feature Extraction from Individual Gray Matter Similarity-Matrix for Alzheimer's Disease Classification. J Alzheimers Dis. 2017;55(4):1571-1582

Beheshti I, Maikusa N, Daneshmand M, Matsuda H, Demirel H, Anbarjafari G; Japanese-Alzheimer’s Disease Neuroimaging Initiative.. Classification of Alzheimer's Disease and Prediction of Mild Cognitive Impairment Conversion Using Histogram-Based Analysis of Patient-Specific Anatomical Brain Connectivity Networks. J Alzheimers Dis. 2017;60(1):295-304

Asser A., Kõks S., Snellman A., Haaparanta-Solin M., Arponen E., Grönroos T., Nairismägi J., Bergquist J., Soomets U., Piip P., Eltermaa M., Sauk M., Lindmäe H., Rinne JO., Taba P. Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese Brain Research: 1652, 97-102, 2016

Juurmaa J., Menke RA., Vila P., Müürsepp A., Tomberg T., Ilves P., Nigul M., Johansen-Berg H., Donaghy M., Stagg CJ., Stepens A6, Taba P. Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome Brain and Behavior: 6 (11), Artikkel nr e00539, 2016

Kadastik-Eerme L., Muldmaa M., Lilles S., Rosenthal M., Taba N., Taba P. Nonmotor Features in Parkinson's Disease: What Are the Most Important Associated Factors? Parkinson's Disease: 2016, Artikkel nr 4370674, 2016

Nõmm S., Toomela A., Vaske M., Uvarov D., Taba P. An Alternative Approach to Distinguish Movements of Parkinson Disease Patients IFAC-PapersOnLine: 49 (19), 272-276, 2016

Rätsep T., Asser T. Placebo effects induced by auditory cues decrease parkinsonian rigidity in patients with subthalamic stimulation Behavioural Brain Research: 301, 27-32, 2016

Sabre L., Braschinsky M., Taba P. Neurosyphilis as a great imitator: a case report BMC Research Notes: 9 (1), Artikkel nr 372, 2016

Toomsoo T., Liepelt-Scarfone I., Kerner R., Kadastik-Eerme L., Asser T., Rubanovitš I., Berg D., Taba P. Substantia Nigra Hyperechogenicity: Validation of Transcranial Sonography for Parkinson Disease Diagnosis in a Large Estonian Cohort Journal of Ultrasound in Medicine: 35 (1), 17-23, 2016

Asser A., Taba P. Psychostimulants and movement disorders Frontiers in Neurology: 6, Artikkel nr UNSP 75, 2015

Kadastik-Eerme L., Rosenthal M., Paju T., Muldmaa M., Taba P. Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms Health and Quality of Life Outcomes: 13, Artikkel nr 83, 2015

Kunze U., International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis as a notifiable disease - Status quo and the way forward. Report of the 17th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Ticks and Tick-borne Diseases: 6 (5), 545-548, 2015

Medijainen K., Pääsuke M., Lukmann A., Taba P. Functional Performance and Associations between Performance Tests and Neurological Assessment Differ in Men and Women with Parkinson's Disease Behavioural Neurology: 2015, Artikkel nr 519801, 2015

Miller DH., Fox RJ., Phillips JT., Hutchinson M., Havrdova E., Kita M., Wheeler-Kingshott CA., Tozer DJ., MacManus DG., Yousry TA., Goodsell M., Yang M., Zhang R., Viglietta V., Dawson KT., Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) Study Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study Neurology: 84 (11), 1145-1152, 2015

Antsov E., Silveira-Moriyama L., Kilk S., Kadastik-Eerme L., Toomsoo T., Lees AJ., Taba P. Adapting the Sniffin' Sticks olfactory test to diagnose Parkinson's disease in Estonia Parkinsonism & Related Disorders: 20 (8), 830-833, 2014

Filippi M., Rocca MA., Pagani E., De Stefano N., Jeffery D., Kappos L., Montalban X., Boyko A., Comi G., Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis (ALLEGRO) Study Group Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage Journal of Neurology, Neurosurgery and Psychiatry: 85 (8), 852-859, 2014

Mencacci NE., Isaias IU., Reich MM., Ganos C., Plagnol V., Polke JM., Bras J., Hersheson J., Stamelou M., Pittman AM., Noyce AJ., Mok KY., Opladen T., Kunstmann E., Hodecker S., Münchau A., Volkmann J., Samnick S., Sidle K., Nanji T., Sweeney MG., Houlden H., Batla A., Zecchinelli AL., Pezzoli G., Marotta G., Lees AJ., Alegria P., Krack P., Cormier-Dequaire F., Lesage S., Brice A., Heutink P., Gasser T., Lubbe SJ., Morris HR., Taba P., Kõks S., Majounie E., Raphael Gibbs J., Singleton AB., Hardy J., Klebe S., Bhatia KP., Wood NW., International Parkinson's Disease Genomics Consortium (IPDGC), University College London Exomes Consortium (UCL-Exomes Consortium) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers Brain: 137 (Pt 9), 2480-2492, 2014

Pahwa R., Lyons KE., Hauser RA., Fahn S., Jankovic J., Pourcher E., Hsu A., O'Connell M., Kell S., Gupta S., APEX-PD Investigators Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease Parkinsonism & Related Disorders: 20 (2), 142-148, 2014

Raudmann M., Taba P., Medijainen K. Handwriting speed and size in individuals with Parkinson’s disease compared to healthy controls: the possible effect of cueing Acta Kinesiologiae Universitatis Tartuensis: 20, 40-47, 2014

Rätsep T., Abel A., Linnamägi Ü. Patient involvement in surgical treatment decisions and satisfaction with the treatment results after lumbar intervertebral discectomy European Spine Journal: 23 (4), 873-881, 2014

Berardelli A., Wenning GK., Antonini A., Berg D., Bloem BR., Bonifati V., Brooks D., Burn DJ., Colosimo C., Fanciulli A., Ferreira J., Gasser T., Grandas F., Kanovsky P., Kostic V., Kulisevsky J., Oertel W., Poewe W., Reese JP., Relja M., Ruzicka E., Schrag A., Seppi K., Taba P., Vidailhet M. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease European Journal of Neurology: 20 (1), 16-34, 2013

Kunze U., International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis - a notifiable disease Report of the 15th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Ticks and Tick-borne Diseases: 4 (5), 363-365, 2013

Lill M., Kõks S., Soomets U., Schalkwyk LC., Fernandes C., Lutsar I., Taba P. Peripheral blood RNA gene expression profiling in patients with bacterial meningitis Frontiers in Neuroscience: 7, Artikli nr 33, 2013

Lubi K., Vihalemm T., Krikmann Ü., Paju T., Taba P. “There is no need to tell me too much”: chronically ill patients’strategies of controlling information inflow International Journal of Communication and Health: 1, 24-30, 2013

Rätsep T., Minajeva A., Asser T. Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs European Spine Journal: 22 (11), 2474-2480, 2013

Sikk K., Haldre S., Aquilonius SM., Asser A., Paris M., Roose Ä., Petterson J., Eriksson SL., Bergquist J., Taba P. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up European Journal of Neurology: 20 (6), 915-920, 2013

Taba P. Metals and movement disorders Current Opinion in Neurology: 26 (4), 435-441, 2013

Taba P., Lees AJ., Stern G. Erich Harnack (1852-1915) and a short history of apomorphine European Neurology: 69 (6), 321-324, 2013

Vetkas A., Lepik T., Eilat T., Rätsep T., Asser T. Emotional health and quality of life after aneurysmal subarachnoid hemorrhage Acta Neurochirurgica: 155 (6), 1107-1114, 2013

Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., Rocca MA., Filippi M., Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis (ALLEGRO) Study Group Placebo-controlled trial of oral laquinimod for multiple sclerosis New England Journal of Medicine: 366 (11), 1000-1009, 2012

Fox RJ., Miller DH., Phillips JT., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser MT., Viglietta V., Dawson KT., Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) Study Investigators. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis New England Journal of Medicine: 367 (12), 1087-1097, 2012

Kunze U., International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis (TBE): an underestimated riskstill: report of the 14th annual meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) Ticks and Tick-borne Diseases: 3 (3), 197-201, 2012

Liik M., Puksa L., Lüüs SM., Haldre S., Taba P. Fulminant inflammatory neuropathy mimicking cerebral death BMJ Case Reports: 2012, 2012

Rätsep T. Postoperative spondylodiscitis caused by Mycobacterium bovis BCG: a case study Spine Journal: 12 (12), E1-E5, 2012

Rätsep T., Asser T. Subthalamic stimulation improves the cerebral hemodynamic response to the cold pressure test in patients with Parkinson's disease Journal of Clinical Ultrasound: 40 (9), 547-553, 2012

Taba P., Rosenthal M., Habicht J., Tarien H., Mathiesen M., Hill SR., Bero LA. Barriers and facilitators to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in Estonia BMC Health Services Research: 12, 455, 2012

Comi G., Cohen JA., Arnold DL., Wynn D., Filippi M., Forty mg efficacy of glatiramer acetate (FORTE) study group Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis Annals of Neurology: 69 (1), 75-82, 2011

Ling H., Braschinsky M., Taba P., Lüüs SM., Doherty K., Hotter A., Poewe W., Lees AJ. Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients Movement Disorders: 26 (7), 1337-1340, 2011

Rätsep T., Asser T. Changes in viscoelastic properties of skeletal muscles induced by subthalamic stimulation in patients with Parkinson's disease Clinical Biomechanics: 26 (2), 213-217, 2011

Sikk K., Haldre S., Aquilonius SM., Taba P. Manganese-Induced Parkinsonism due to Ephedrone Abuse Parkinson's Disease: 2011 (1), 2011

Sikk K., Kõks S., Soomets U., Schalkwyk LC., Fernandes C., Haldre S., Aquilonius SM., Taba P. Peripheral blood RNA expression profiling in illicit methcathinone users reveals effect on immune system Frontiers in Genetics: 2, 42, 2011

A'Campo LEI., Spliethoff-Kamminga NGA., Macht M., Roos RAC., Patient education in parkinson's disease (EduPark) Caregiver education in Parkinson's disease: formative evaluation of a standardized program in seven European countries Quality of Life Research: 19 (1), 55-64, 2010

Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Sorensen PS., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg SJ., Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) Study Group A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis New England Journal of Medicine: 362 (5), 416-426, 2010

Sikk K., Taba P., Haldre S., Bergquist J., Nyholm D., Askmark H., Danfors T., Sörensen J., Thurfjell L., Raininko R., Eriksson R., Flink R., Färnstrand C., Aquilonius SM. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure Acta Neurologica Scandinavica: 121 (4), 237-243, 2010

Krikmann Ü., Taba P., Lai T., Asser T. Validation of an Estonian version of the Parkinson's Disease Questionnaire (PDQ-39) Health and Quality of Life Outcomes: 6, Artikli nr 23, 2008

Lewis SC., Warlow CP., Bodenham AR., Colam B., Rothwell PM., Torgerson D., Dellagrammaticas D., Horrocks M., Liapis C., Banning AP., Gough M., Gough MJ., General anaesthesia versus local anaesthesia for carotid surgery (GALA) trial collaborative group General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial The Lancet: 372 (9656), 2132 - 2142, 2008

Macht M., Gerlich C., Ellgring H., Schradi M., Rusinol AB., Crespo M., Prats A., Viemero V., Lankinen A., Bitti PER., Candini L., Spliethoff-Kamminga NGA., de Vreugd J., Simons G., Pasqualini MS., Thompson SBN., Taba P., Krikmann Ü., Kanarik E. Patient education in Parkinson's disease: Formative evaluation of a standardized programme in seven European countries Patient Education and Counseling: 65 (2), 245-252, 2007

Macht M., Pasqualini MS., Taba P. Cognitive-behavioral strategies for Parkinson's disease: A report of three cases Journal of Clinical Psychology in Medical Settings: 14 (2), 165-176, 2007

Sikk K., Taba P., Haldre S., Bergquist J., Nyholm D., Zjablov G., Asser T., Aquilonius SM. Irreversible motor impairment in young addicts - ephedrone, manganism or both? Acta Neurologica Scandinavica: 115 (6), 385-389, 2007

Publikatsioonid ajakirjas „Eesti Arst“

Ambos A., Raie E., Kiudma T., Reppo I., Rätsep A., Tammiksaar K., Toomsoo T., Volke V. 2. tüüpi diabeedi Eesti ravijuhend 2016 Eesti Arst: 95 (7), 465-473, 2016

Rallmann K., Liik M., Taba P. Botulismitoksiini kliiniline kasutamine Eesti Arst: 95 (3), 171-178, 2016

Taba P. Muusika müstika: kas emotsionaalne nauding või ravimeetod? Eesti Arst: 95 (11), 749-749, 2016

Hunt H., Säälik P., Toome K., Vetkas A., Asser A., Rätsep T., Asser T., Teesalu T. Hõbekuulid vähiteraapias: teel suunatud vähiravi poole Eesti Arst: 94 (5), 281-287, 2015

Toomsoo T., Asser T., Taba P. Transkraniaalne ultraheliuuring Parkinsoni tõve diagnoosimisel Eesti Arst: 94 (Lisa 4), 100-105, 2015

Lubi K., Vihalemm T., Taba P. Patsiendid infootsijana: väljakutsed, võimalused ja ohud Parkinsoni tõvega patsientide näitel Eesti Arst: 93 (2), 76-82, 2014

Sikk K., Haldre S., Aquilonius SM., Taba P. Toksiline parkinsonism psühhostimulanti süstivatel noortel narkomaanidel Eesti Arst: 92 (6), 320-324, 2013

Vetkas A., Mehevits K., Rätsep T., Asser T. Spontaanse subarahnoidaalse hemorraagia diagnoosimise kiirus ja seda mõjutavad tegurid Eesti Arst: 90 (8), 366-371, 2011

Kõrv J., Gross-Paju K., Haldre S., Jaakmees H., Kreis A., Kullamaa S., Liigant A., Lüüs SM., Taba P., Õunapuu A. Insuldi käsitlus Eestis: hetkeseis ja suundumused Eesti Arst: 89 (6), 409-415, 2010

Krikmann Ü., Kalbe I., Lüüs SM., Taba P., Õunapuu A. Neuroborrelioos - puukidega leviv närvisüsteemi bakternakkus Eesti Arst: 87 (3), 214-220, 2008

Toomsoo T., Taba P. Treemorid Eesti Arst: 87 (6), 424-430, 2008

Braschinsky M., Vibo R., Rallmann K., Asser A., Tomberg T. Aju venoossete siinuste tromboos Eesti Arst: 86 (12), 897-902, 2007

Krikmann Ü., Kalbe I., Lüüs SM., Taba P., Õunapuu A. Puukentsefaliit – sage närvisüsteeemi viirushaigus Eesti Arst: 86 (4), 273-276, 2007

Lill M., Seeman S., Taba P., Lüüs SM. Locked-in sündroom Eesti Arst: 85 (6), 387-393, 2006

Raamatud, peatükid raamatutes:

Lubi K., Vihalemm T., Taba P. Patients’ interpretations of CAM-related information: manoeuvring between patient and consumer positionings The Power of the Media in Health Communication: 71-90, 2016

Stepens A., Taba P. The Neuropathology of Movement Disorders in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone (Ephedrone) Addictions Neuropathology of Drug Addictions and Substance Misuse: 3, 924–934, 2016

Jürisson M., Taba P., Võrno T., Abram M., Eiche IE., Uusküla A. Puukentsefaliidivastase vaktsineerimise kulutõhusus Eestis Puukentsefaliidivastase vaktsineerimise kulutõhusus Eestis: 111, 2015

Lees AJ., Sikk K., Taba P. The Story of "Speed" from "Cloud Nine" to Brain Gain International Review of Neurobiology: 120, 1-7, 2015

Sikk K., Taba P. Methcathinone “Kitchen Chemistry” and Permanent Neurological Damage International Review of Neurobiology: 120, 257-271, 2015

Taba P., Lees AJ., Sikk K. The Neuropsychiatric Complications of Stimulant Abuse The Neuropsychiatric Complications of Stimulant Abuse: 388, 2015

Taba P., Lutsar I. Chronic Infectious Inflammatory Diseases of the Central Nervous System Cerebrospinal Fluid in Clinical Neurology: 211-245, 2015

Lubi K., Vihalemm T., Taba P. Illness-related Information Seeking: The Case of Parkinson's Disease Patients Advances in Education Research. 2014 2nd International Conference on Social Science and Health (ICSSH 2014): 59, 98-111, 2014

Taba P. Movement disorders associated with chronic metal poisoning Movement Disorders in Neurologic and Systemic Disease: 220-233, 2014

Sikk K. Manganese-ephedrone intoxication – pathogenesis of neurological damage and clinical symptomatology Dissertationes medicinae Universitatis Tartuensis: 206, 125, 2013

Taba P. Parkinsoni tõve ravi Eakate farmakoteraapia: 307-318, 2012

Taba P., Krikmann Ü., Kanarik E. Introduccion. Informacion Psicoeducation para afectados de Parkinson y sus cuidadores: 23-43, 2007

Uueni D., Pääsuke M., Gapeyeva H., Ereline J., Kums T., Noorvee K., Taba P. Motoorse võimekuse näitajad mõõdukalt väljendunud Parkinsoni tõvega patsientidel ja kontrollgrupil Kehakultuuriteaduskonna teadus- ja õppemetoodiliste tööde kogumik: 85-94, 2007

Macht M., Ellgring H., Gerlich C., Haapaniemi H., Krikmann Ü., Leino P., Routasalo P., Taba P. Informationsbedürfnisse bei Parkinson-Patienten in Estland, Finnland und Deutschland Beschreiben – Erschließen – Erläutern: Psychotherapieforschung als qualitative Wissenschaft: 340-353, 2006

Taba P., Krikmann Ü., Kanarik E. Einfürhung in das Programm und Informationssuche Psychosoziales Training bei neurologischen Erkrankungen - Schwerpunkt Parkinson. Ein Programm für die Schulung von Patienten und Angehörigen: 39-51, 2006

Taba P., Krikmann Ü., Kanarik E. Information Patient education for people with Parkinson's disease and their carers : a manual / edited by Marcia Smith Pasqualini and Gwenda Simons: 27-46, 2006

Taba P., Krikmann Ü., Kanarik E. Introduzione Intervento psicoeducativo nella malattia di Parkinson : il programma EduPark/ Pio Enrico Ricci Bitti ... [et al.]: 45-65, 2006

Sikk K. Manganese-ephedrone intoxication – pathogenesis of neurological damage and clinical symptomatology Dissertationes medicinae Universitatis Tartuensis: 206, 125, 2013

Taba P. Parkinsoni tõve ravi Eakate farmakoteraapia: 307-318, 2012

Taba P., Krikmann Ü., Kanarik E. Introduccion. Informacion Psicoeducation para afectados de Parkinson y sus cuidadores: 23-43, 2007

Uueni D., Pääsuke M., Gapeyeva H., Ereline J., Kums T., Noorvee K., Taba P. Motoorse võimekuse näitajad mõõdukalt väljendunud Parkinsoni tõvega patsientidel ja kontrollgrupil Kehakultuuriteaduskonna teadus- ja õppemetoodiliste tööde kogumik: 85-94, 2007

Macht M., Ellgring H., Gerlich C., Haapaniemi H., Krikmann Ü., Leino P., Routasalo P., Taba P. Informationsbedürfnisse bei Parkinson-Patienten in Estland, Finnland und Deutschland Beschreiben – Erschließen – Erläutern: Psychotherapieforschung als qualitative Wissenschaft: 340-353, 2006

Taba P., Krikmann Ü., Kanarik E. Einfürhung in das Programm und Informationssuche Psychosoziales Training bei neurologischen Erkrankungen - Schwerpunkt Parkinson. Ein Programm für die Schulung von Patienten und Angehörigen: 39-51, 2006

Taba P., Krikmann Ü., Kanarik E. Information Patient education for people with Parkinson's disease and their carers : a manual / edited by Marcia Smith Pasqualini and Gwenda Simons: 27-46, 2006

Taba P., Krikmann Ü., Kanarik E. Introduzione Intervento psicoeducativo nella malattia di Parkinson : il programma EduPark/ Pio Enrico Ricci Bitti ... [et al.]: 45-65, 2006

Muud publikatsioonid

Taba P. Treemorid Perearst: 6 (104), 44-47, 2015

Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E., Ankru K., Kivil H., Taurafeldt E., Aasa M. Болезнь Паркинсона : книга для больных и их семей. III Болезнь Паркинсона : книга для больных и их семей. III: 106 lk, 2012

Taba P. Ludvig Puusepa nim Neuroloogide ja Neurokirurgide Selts 2009. aastal Lege Artis: 6(96), 37-37, 2010

Taba P. Parkinsoni tõve ravi - probleemid ja lahendused Lege Artis: 5(95), 11-16, 2010

Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E., Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõve Eesti ravijuhend Parkinsoni tõve Eesti ravijuhend: 102, 2008

Toomsoo T. Naised ja migreen - kas insuldi risk on suurem? Lege Artis: Lisa (juuni), 35-38, 2008

Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E., Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõbi: raamat haigetele ja nende peredele III Parkinsoni tõbi: raamat haigetele ja nende peredele III: 104, 2007

Toomsoo T. Rasagiliin teeb soovitud tulemuse lihtsaks Hippokrates: 9 (80), 354-356, 2007